Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Terminated Phase 2 Interventional Results available

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neural Substrates of Emotion: Impact of Cocaine Dependence

NCT02682784
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949
View directory record Official record
Conditions
Smoking Cessation
Interventions
Cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107
View directory record Official record
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed No phase listed Observational Results available

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

NCT05080192
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Attention Bias Modification Training for Child Anxiety CBT Nonresponders

NCT01819311
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Attention Bias Modification, Placebo Attention Task
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
8 Years to 16 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

NCT06723171
View directory record Official record
Conditions
Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
Interventions
IRX4204, Placebo
Drug · Other
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Not applicable Interventional

Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome

NCT03717532
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Placebo, Personalized Tourniquet System for Blood Flow Restriction
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06474 in Healthy Young Men

NCT05003687
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

NCT05211947
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 51 Years
Enrollment
1,356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
49
States / cities
Anaheim, California • Bellflower, California • Culver City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 4 Interventional

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Atorvastatin calcium, Inactive Placebo
Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
25 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Feasibility, Effectiveness and Efficacy of the PowerSleep Device

NCT02797678
View directory record Official record
Conditions
Sleep, Sleep Disorders Not Due to A Substance or Known Physiological Condition
Interventions
Powersleep, Sham Powersleep
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Chesterfield, Missouri • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vyvanse in Children Aged 6 to 12 Years

NCT05416125
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Lisdexamfetamine Dimesylate, Lifestyle therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

NCT06857617
View directory record Official record
Conditions
Obesity and Overweight
Interventions
(Part C) MET097, (Part C) Placebo
Biological
Lead sponsor
Metsera, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 1 Interventional

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

NCT01367990
View directory record Official record
Conditions
Alopecia, Radiodermatitis
Interventions
Norepinephrine
Drug
Lead sponsor
ProCertus BioPharm, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

NCT01132118
View directory record Official record
Conditions
Rheumatoid Arthritis, Insulin Resistance
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
PF-06700841, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
30
States / cities
Rogers, Arkansas • Anaheim, California • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Intervention to End Recurrent Unscheduled Bleeding Trial

NCT03118297
View directory record Official record
Conditions
Contraception, Bleeding
Interventions
Ulipristal Acetate, Placebo oral capsule
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548
View directory record Official record
Conditions
Huntington's Disease
Interventions
20 mg BID of PF-02545920
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 66 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 30, 2026, 7:16 PM EDT
Withdrawn Phase 4 Interventional

Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision

NCT05082155
View directory record Official record
Conditions
Surgical Incision, Pain, Postoperative, Pain, Acute
Interventions
Bupivacaine 0.25%, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

NCT01673555
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 7:16 PM EDT